?”; “You feel warm; let’s take your temperature.”; “You have a fever; we are going to the emergency room.” I further think that having a reliable support system (eg, mothers, spouses, significant others, friends) has a major influence on outcomes of therapy
Search Results
Don’t Give Up – They Eventually Grow Up: Issues in AYA Medicine
Peter F. Coccia
Safety at the Time of the COVID-19 Pandemic: How to Keep Our Oncology Patients and Healthcare Workers Safe
Pelin Cinar, Timothy Kubal, Alison Freifeld, Asmita Mishra, Lawrence Shulman, James Bachman, Rafael Fonseca, Hope Uronis, Dori Klemanski, Kim Slusser, Matthew Lunning, and Catherine Liu
symptoms such as a new or worsening cough within the past 14 days, shortness of breath, muscle aches, or fever, and may also include assessment of exposure risk, including travel history or exposure to a COVID-19–positive individual. If any concerning
Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence
Gary H. Lyman
R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 18 Trillet-Lenoir V Green J Manegold C
Antimicrobial Stewardship in Cancer Patients: The Time is Now
Samuel L. Aitken, Jerod L. Nagel, Lilian Abbo, William Alegria, Jason N. Barreto, Sanjeet Dadwal, Alison G. Freifeld, Rupali Jain, Steven A. Pergam, Frank P. Tverdek, Susan K. Seo, and on behalf of the Antimicrobial Stewardship in Cancer Consortium ASCC
-specific, evidence-based guidelines and clinical pathways to standardize prescribing is not only feasible but necessary. Examples of highly used pathways in patients with cancer include the management of fever and neutropenia, antifungal prophylaxis and treatment
Infusion-Compatible Antibiotic Formulations for Rapid Administration to Improve Outcomes in Cancer Outpatients With Severe Sepsis and Septic Shock: The Sepsis STAT Pack
Jason D. Goldman, Amelia Gallaher, Rupali Jain, Zach Stednick, Manoj Menon, Michael J. Boeckh, Paul S. Pottinger, Stephen M. Schwartz, and Corey Casper
uncomplicated neutropenic fever, but differ regarding which antibiotics should be included in combination therapy for initial management of SS/SSh, reflecting sparse and conflicting data in patients with cancer and SS/SSh. We reasoned that intervening in the
Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use
Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre, and Gary H. Lyman
Background Neutropenia is a common side effect of myelosuppressive chemotherapy that increases the risk of infection, which is typically signaled by fever. When neutropenic patients develop fever (ie, febrile neutropenia [FN]), the likelihood
Long-Term Outcomes of Myeloid Growth Factor Treatment
Gary H. Lyman and David C. Dale
( ELANE ). 21 , 22 Patients with cyclic neutropenia have oscillations in blood neutrophils usually at 3-week intervals, measured from nadir to nadir. During the period of most severe neutropenia, fever, severe mouth ulcers, pharyngitis, sinusitis, anal
NCCN News
fevers, sweats, weight loss, and pneumonia. A surgical biopsy is often required to effectively diagnose a patient with mesothelioma according to Dr. Krug. PET scans can aid in staging as well, detecting unexpected metastases in 10 percent of cases
Neoadjuvant Imatinib for Borderline Resectable GIST
M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz
emergency department with nausea, vomiting, fevers, tachycardia, and an elevated WBC count. CT showed new gas within the tumor, consistent with liquefaction necrosis. She was treated with antibiotics and discharged on continued imatinib. A contrast CT after
Melanoma, Version 4.2014
Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, and Maria Ho
or higher adverse events occurred in 53% of patients receiving dabrafenib, although grade 3 or 4 events were uncommon. The most frequent side effects were skin-related toxicity, fever, fatigue, arthralgia, and headache. Compared with vemurafenib
